Jobs
-
The FDA has issued a draft guidance on bioequivalence recommendations for generic fluticasone propionate/salmeterol xinafoate inhalers. Notice of the draft guidance appeared in the Federal Register for September 10, 2013. According to the agency, public… Read more . . .
-
Boehringer Ingelheim has presented new data from several Phase 3 studies of olodaterol for the treatment of COPD and from the TIOSPIR tiotropium Respimat study at the European Respiratory Society (ERS) Annual Congress 2013. Data… Read more . . .
-
Smartinhaler manufacturer Nexus6 has announced three new management appointments: Veronique Bouchet as VP of Business Development for Europe, Christopher Stevens as Chief Operating Officer, and Chris Mander as Head of Regulatory and Quality. According to… Read more . . .
-
Capsugel will acquire Bend Research for an undisclosed amount, the companies have announced. Bend will become part of Capsugel’s Dosage Form Solutions (DFS) business unit. Although the press release highlights Capsugel’s new “access to a… Read more . . .
-
Theravance has announced that a dose-ranging 7-day Phase 2b study of TD‑4208 inhalation solution, an investigational long-acting muscarinic antagonist (LAMA) for the treatment of COPD, met its primary endpoints for all six doses. TD-4208 showed… Read more . . .
-
Civitas Therapeutics has initiated a 28-day Phase 2b efficacy and safety study of CVT-301 inhaled levodopa for the treatment of intermittent motor fluctuations in Parkinson’s patients, the company said. The study is partially funded by… Read more . . .
-
A study appearing online first in the New England Journal of Medicine finds that “Tiotropium Respimat at a dose of 5 μg or 2.5 μg had a safety profile and exacerbation efficacy similar to those… Read more . . .
-
Swedish pharmaceutical company Meda has agreed to acquire Massachusetts-based Acton Pharmaceuticals for $135 million plus a $10 million milestone payment and royalty milestones. According to Acton, the deal could be worth up to $200 million.… Read more . . .
-
Opthalmic and injectables manufacturer Akorn will acquire Hi-Tech Pharmacal for $640 million in cash, the companies said. Hi-Tech Pharmacal’s products include generic albuterol inhalation solution and fluticasone nasal spray, plus several OTC intranasal products. The… Read more . . .
-
The Respiratory Technology Team of the Woolcock Institute for Medical Research (WIMR) has announced that a $12,000 International Research Collaboration Award from the University of Sydney will fund a collaboration between the team and Carsten… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK